BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34638388)

  • 21. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
    Zhang D; Whitaker B; Derebe MG; Chiu ML
    MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer.
    Sewnath CA; Behrens LM; van Egmond M
    Expert Opin Biol Ther; 2022 Aug; 22(8):983-995. PubMed ID: 35854649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 26. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression.
    Wettersten HI; Weis SM; Pathria P; Von Schalscha T; Minami T; Varner JA; Cheresh DA
    Cancer Res; 2019 Oct; 79(19):5048-5059. PubMed ID: 31416839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
    Lu H; Molony RD; Chen D; Jang S; Wolf B; Ewert S; Flaherty M; Xu F; Isim S; Shim Y; Dornelas C; Balke N; Leber XC; Scharenberg M; Koelln J; Choi E; Ward R; Johnson J; Calzascia T; Isnardi I; Williams JA; Lindenbergh PL; van de Donk NWCJ; Mutis T; Huet H; Lees E; Meyer MJ
    Mol Cancer Ther; 2020 Oct; 19(10):2089-2104. PubMed ID: 32847974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
    Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
    Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.
    Nagashima H; Ootsubo M; Fukazawa M; Motoi S; Konakahara S; Masuho Y
    J Biosci Bioeng; 2011 Apr; 111(4):391-6. PubMed ID: 21215693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.
    Zhou X; Liu X; Huang L
    Adv Funct Mater; 2021 Jan; 31(5):. PubMed ID: 33692665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.
    Díaz de León JSA; Aguilar I; Barb AW
    Glycobiology; 2023 Dec; 33(12):1182-1192. PubMed ID: 37792857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
    Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
    Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses.
    Tay MZ; Wiehe K; Pollara J
    Front Immunol; 2019; 10():332. PubMed ID: 30873178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precise Delivery of Nanomedicines to M2 Macrophages by Combining "Eat Me/Don't Eat Me" Signals and Its Anticancer Application.
    Tang Y; Tang Z; Li P; Tang K; Ma Z; Wang Y; Wang X; Li C
    ACS Nano; 2021 Nov; 15(11):18100-18112. PubMed ID: 34751571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
    Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
    Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.